Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements

NCT00559949 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00559949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00559949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
August 31, 2016
Enrollment
39 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent thyroid gland carcinoma, stage i thyroid gland papillary carcinoma, stage ii thyroid gland papillary carcinoma, stage iii thyroid gland papillary carcinoma, stage iv thyroid gland papillary carcinoma